These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29424120)

  • 41. On hybrid parallel-crossover designs for assessing drug interchangeability of biosimilar products.
    Chow SC; Song F; Cui C
    J Biopharm Stat; 2017; 27(2):265-271. PubMed ID: 28026996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. On Statistical Approaches for Demonstrating Analytical Similarity in the Presence of Correlation.
    Yang H; Novick S; Burdick RK
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):547-559. PubMed ID: 27325594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacist Substitution of Biological Products: Issues and Considerations.
    Li E; Ramanan S; Green L
    J Manag Care Spec Pharm; 2015 Jul; 21(7):532-9. PubMed ID: 26108377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biosimilars: The US Regulatory Framework.
    Christl LA; Woodcock J; Kozlowski S
    Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.
    Dowlat HA; Kuhlmann MK; Khatami H; Ampudia-Blasco FJ
    Diabetes Obes Metab; 2016 Aug; 18(8):737-46. PubMed ID: 27097592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M; Coiffier B; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. On the establishment of equivalence acceptance criterion in analytical similarity assessment.
    Wang T; Chow SC
    J Biopharm Stat; 2017; 27(2):206-212. PubMed ID: 28051920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design and Analysis of a Biosimilar Bridging Study with a Prediction Interval-Based Consistency Test.
    Pan Z; Huang W; Pan J; Koch G
    Ther Innov Regul Sci; 2021 Jul; 55(4):765-772. PubMed ID: 33797059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analytical Similarity Assessment in Biosimilar Studies.
    Chow SC; Song F; Bai H
    AAPS J; 2016 May; 18(3):670-7. PubMed ID: 26873509
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The safety of switching between therapeutic proteins.
    Ebbers HC; Muenzberg M; Schellekens H
    Expert Opin Biol Ther; 2012 Nov; 12(11):1473-85. PubMed ID: 22849511
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bioanalytical challenges of biosimilars.
    Islam R
    Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data.
    López-Siguero JP; Pfäffle R; Chanson P; Szalecki M; Höbel N; Zabransky M
    Drug Des Devel Ther; 2017; 11():1489-1495. PubMed ID: 28553079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDA's Approach to Regulating Biosimilars.
    Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.
    Nikiphorou E; Kautiainen H; Hannonen P; Asikainen J; Kokko A; Rannio T; Sokka T
    Expert Opin Biol Ther; 2015; 15(12):1677-83. PubMed ID: 26549204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Switching from one drug therapy to another with the same therapeutic indication without harms.].
    Belleudi V; Addis A
    Recenti Prog Med; 2017 Nov; 108(11):451-453. PubMed ID: 29149162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SB2: An Infliximab Biosimilar.
    Lamb YN; Scott LJ; Deeks ED
    BioDrugs; 2017 Oct; 31(5):461-464. PubMed ID: 28803431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.